Case Study: Drug Discovery AI Consortium

Foundational AI models for drug discovery have made a huge leap forward over the last 2 years. However, limited availability of high-quality molecular data is a major bottleneck to achieving the next steps forward. The AI Structural Biology Consortium was created to tackle these challenge and unblock the next revolutions in AI-driven drug discovery.

In this case study we explore:

checkmark The challenges around access to high-quality molecular data for Life Sciences
checkmark How the Consortium consisting of major pharmaceutical companies, prestigious model building partners and Apheris as the technology provider was created to tackle this
checkmark The use cases including model benchmarking & fine-tuning
checkmark Leveraging Federation to ensure secure, governed and privacy preserving collaboration between all parties

Recommended for you